Top

Published in:

Open Access 27-02-2024 | Cytostatic Therapy | Peritoneal Surface Malignancy

Expanding the Use of HIPEC in Ovarian Cancer at Time of Interval Debulking Surgery to FIGO Stage IV and After 6 Cycles of Neoadjuvant Chemotherapy: A Prospective Analysis on Perioperative and Oncologic Outcomes

Authors: Valentina Ghirardi, MD, Rita Trozzi, MD, Francesca Romana Scanu, MD, Diana Giannarelli, MD, Francesco Santullo, MD, Barbara Costantini, MD, Angelica Naldini, MD, Camilla Panico, MD, Luciano Frassanito, MD, Giovanni Scambia, MD, Anna Fagotti, MD, PhD

Published in: Annals of Surgical Oncology | Issue 5/2024

Abstract

Background

Randomized data on patients with FIGO stage III ovarian cancer receiving ≤ 3 cycles of neoadjuvant chemotherapy (NACT) showed that hyperthermic intraperitoneal chemotherapy (HIPEC) after interval debulking surgery (IDS) improved patient’s survival. We assessed the perioperative outcomes and PFS of FIGO stage IV and/or patients receiving up to 6 cycles of NACT undergoing IDS+HIPEC.

Methods

Prospectively collected cases from January 1, 2019 to July 31, 2022 were included. Patients underwent HIPEC if: age ≥ 18 years but < 75 years, body mass index ≤ 35 kg/m², ASA score ≤ 2, FIGO stage III/IV epithelial disease treated with up to 6 cycles of NACT, and residual disease < 2.5 mm.

Results

A total of 205 patients were included. No difference was found in baseline characteristics between FIGO Stage III and IV patients, whereas rate of stable disease after NACT (p = 0.004), mean surgical complexity score at IDS (p = 0.001), and bowel resection rate (p = 0.046) were higher in patients undergoing delayed IDS. A lower rate of patients with at least one G3–G5 postoperative complications was observed in FIGO stage IV versus FIGO stage III disease (5.3% vs. 14.0%; p = 0.052). This difference was confirmed at multivariable analysis (odds ratio [OR] 0.24; 95% confidence interval [CI] 0.07–0.80; p = 0.02), whereas age, SCS, bowel resection, and number of cycles did not affect postoperative complications. No difference in PFS was identified neither between FIGO stage III and IV patients (p = 0.44), nor between 3 and 4 versus > 4 cycles of NACT (p = 0.85).

Conclusions

Because of the absence of additional complications and positive survival outcomes, HIPEC administration can be considered in selected FIGO stage IV and patients receiving > 4 cycles of NACT.

Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Vos LMC, Aronson SL, van Driel WJ, et al. Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2022;78:86–102. https://doi.org/10.1016/j.bpobgyn.2021.06.004.CrossRefPubMed

vanDrielWJ KooleSN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230–40. https://doi.org/10.1056/NEJMoa1708618.CrossRef

Armstrong DK, Alvarez RD, Backes FJ, et al. NCCN guidelines® insights: ovarian cancer, version 3.2022. J Natl Compr Canc Netw. 2022;20(9):972–80. https://doi.org/10.6004/jnccn.2022.0047.CrossRefPubMed

Ghirardi V, Ronsini C, Trozzi R, et al. Hyperthermic intraperitoneal chemotherapy in interval debulking surgery for advanced epithelial ovarian cancer: a single center, real-life experience. Cancer. 2020;126:5256–62. https://doi.org/10.1002/cncr.33167.CrossRefPubMed

Prat J. FIGO committee on gynecologic oncology staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication of guidelines from the international federation of gynecology and obstetrics (FIGO). Obstet Gynecol. 2015;126(1):171–4. https://doi.org/10.1097/AOG.0000000000000917.CrossRefPubMed

Fagotti A, Ferrandina G, Fanfani F, et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol. 2006;13(8):1156–61. https://doi.org/10.1245/ASO.2006.08.021.CrossRefPubMed

Segura-Sampedro JJ, Morales-Soriano R, Pineño Flores C, et al. Laparoscopy technique in the setting of peritoneal metastases to avoid port site relapse. Surg Oncol. 2021;37:101543. https://doi.org/10.1016/j.suronc.2021.101543.CrossRefPubMed

Lindemann K, Kok PS, Stockler M, et al. Enhanced recovery after surgery for advanced ovarian cancer: a systematic review of interventions trialed. Int J Gynecol Cancer. 2017;27(6):1274–82. https://doi.org/10.1097/IGC.0000000000000981.CrossRefPubMed

10.

Fagotti A, Ferrandina G, Fanfani F, et al. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol. 2008;199(6):642.e1-6. https://doi.org/10.1016/j.ajog.2008.06.052.CrossRefPubMed

11.

Nitecki R, Rauh-Hain JA, Melamed A, et al. Laparoscopic cytoreduction after neoadjuvant chemotherapy (LANCE). Int J Gynecol Cancer. 2020;30(9):1450–4. https://doi.org/10.1136/ijgc-2020-001584.CrossRefPubMedPubMedCentral

12.

Sugarbaker PH. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol. 2001;27(3):239–43. https://doi.org/10.1053/ejso.2000.1038. (PMID: 11373099).CrossRefPubMed

13.

National Cancer Institute. Common Terminology Criteria for Adverse Events CTCAE. Accessed September 2023. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf

14.

Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13. https://doi.org/10.1097/01.sla.0000133083.54934.CrossRefPubMedPubMedCentral

15.

Lomnytska M, Karlsson E, Jonsdottir B, et al. Peritoneal cancer index predicts severe complications after ovarian cancer surgery. Eur J Surg Oncol. 2021;47(11):2915–24. https://doi.org/10.1016/j.ejso.2021.05.019.CrossRefPubMed

16.

Colombo PE, Labaki M, Fabbro M, et al. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 2014;135(2):223–30. https://doi.org/10.1016/j.ygyno.2014.09.002.CrossRefPubMed

17.

Marchetti C, Rosati A, De Felice F, et al. Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: a propensity-score matching analysis. Gynecol Oncol. 2021;163(1):29–35. https://doi.org/10.1016/j.ygyno.2021.07.025.CrossRefPubMed

18.

Liu YL, Zhou QC, Iasonos A, et al. Preoperative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial sloan kettering cancer center team ovary study. Int J Gynecol Cancer. 2020;30(12):1915–21. https://doi.org/10.1136/ijgc-2020-001641.CrossRefPubMedPubMedCentral

19.

Plett H, Filippova OT, Garbi A, et al. Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. Gynecol Oncol. 2020;159(2):434–41. https://doi.org/10.1016/j.ygyno.2020.08.028.CrossRefPubMedPubMedCentral

20.

Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer (GOGER-01). Available at https://clinicaltrials.gov/ct2/show/NCT02125513. Accessed 12 April 2023.

21.

Classe JM, Ferron G, Ouldamer L, et al. CHRONO: randomized trial of the CHROnology of surgery after neoadjuvant chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2022;32(8):1071–5. https://doi.org/10.1136/ijgc-2021-003320.CrossRefPubMed

22.

Marrelli D, Petrioli R, Cassetti D, et al. A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer. Surg Oncol. 2021;37:101523. https://doi.org/10.1016/j.suronc.2021.101523.CrossRefPubMed

23.

Jamieson A, Sykes P, Eva L, et al. Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence. Gynecol Oncol. 2017;146(2):273–8. https://doi.org/10.1016/j.ygyno.2017.05.023.CrossRefPubMed

24.

Timmermans M, Sonke GS, Van de Vijver KK, et al. Localization of distant metastases defines prognosis and treatment efficacy in patients with FIGO stage IV ovarian cancer. Int J Gynecol Cancer. 2019;29(2):392–7. https://doi.org/10.1136/ijgc-2018-000100.CrossRefPubMed

25.

Aletti GD, Podratz KC, Cliby WA, et al. Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment. Gynecol Oncol. 2009;112(1):22–7. https://doi.org/10.1016/j.ygyno.2008.09.010.CrossRefPubMed

26.

Winter WE 3rd, Maxwell GL, Tian C, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2008;26(1):83–9. https://doi.org/10.1200/JCO.2007.13.1953.CrossRefPubMed

27.

Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006;107(1):77–85. https://doi.org/10.1097/01.AOG.0000192407.04428.bb.CrossRefPubMed

28.

Lee JY, Lee YJ, Son JH, et al. Hyperthermic intraperitoneal chemotherapy after interval cytoreductive surgery for patients with advanced-stage ovarian cancer who had received neoadjuvant chemotherapy. JAMA Surg. 2023. https://doi.org/10.1001/jamasurg.2023.3944.CrossRefPubMedPubMedCentral

Title: Expanding the Use of HIPEC in Ovarian Cancer at Time of Interval Debulking Surgery to FIGO Stage IV and After 6 Cycles of Neoadjuvant Chemotherapy: A Prospective Analysis on Perioperative and Oncologic Outcomes
Authors: Valentina Ghirardi, MD
Rita Trozzi, MD
Francesca Romana Scanu, MD
Diana Giannarelli, MD
Francesco Santullo, MD
Barbara Costantini, MD
Angelica Naldini, MD
Camilla Panico, MD
Luciano Frassanito, MD
Giovanni Scambia, MD
Anna Fagotti, MD, PhD
Publication date: 27-02-2024
Publisher: Springer International Publishing
Keywords: Cytostatic Therapy
Ovarian Cancer
Ovarian Cancer
Published in: Annals of Surgical Oncology / Issue 5/2024
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-024-15042-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Expanding the Use of HIPEC in Ovarian Cancer at Time of Interval Debulking Surgery to FIGO Stage IV and After 6 Cycles of Neoadjuvant Chemotherapy: A Prospective Analysis on Perioperative and Oncologic Outcomes

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2024

Prognostic Significance of Biologic Factors in Patients with a Modest Radiologic Response to Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancers: Impact of the Combination Index of Sialyl-Lewis Antigen-Related Tumor Markers

Preoperative CA 19-9 Predicts Disease Progression in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Analysis from the US HIPEC Collaborative

Clipping a Positive Lymph Node Improves Accuracy of Nodal Staging After Neoadjuvant Chemotherapy for Breast Cancer Patients, but Does It Drive Management Changes?

Nonlinear Associations of Adipose Tissue Metrics with Short-Term Postoperative Complications in Clear Cell Renal Cell Carcinoma Patients

ASO Visual Abstract: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy to Treat Pseudomyxoma Peritonei of Ovarian Origin: A Retrospective French RENAPE Group Study

Gross Hematuria Does not Affect the Selection of Nephrectomy Types for Clinical Stage 1 Clear Cell Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study